Seventy‐two weeks of peginterferon and ribavirin for patients with partial early virologic response?
John C. Hoefs, Timothy R. Morgan – 28 November 2007
Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived
Pere Ginès, Mónica Guevara – 28 November 2007
Modified outflow reconstruction with a venous patch in domino liver transplantation
Matteo Cescon, Gian Luca Grazi, Matteo Ravaioli, Alessandro Cucchetti, Giorgio Ercolani, Antonio Daniele Pinna – 28 November 2007
Surgical stress and tumor behavior: Impact of ischemia‐reperfusion and hepatic resection on tumor progression
Michitaka Ozaki, Satoru Todo – 28 November 2007
Liver and partial atrium transplantation for chronic Budd‐Chiari syndrome
Matteo Ravaioli, Matteo Cescon, Elisa Mikus, Gian Luca Grazi, Giorgio Ercolani, Takuya Kimura, Francesco Tuci, Piero Maria Mikus, Mauro Bernardi, Antonio Daniele Pinna – 28 November 2007
Gut‐derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin‐6/signal transducer and activator of transcription 3 activity
John G. Lunz, Susan M. Specht, Noriko Murase, Kumiko Isse, Anthony J. Demetris – 28 November 2007 – Intraorgan dendritic cells (DCs) monitor the environment and help translate triggers of innate immunity into adaptive immune responses. Liver‐based DCs are continually exposed, via gut‐derived portal venous blood, to potential antigens and bacterial products that can trigger innate immunity. However, somehow the liver avoids a state of perpetual inflammation and protects central immune organs from overstimulation.
Pegylated interferon alpha‐2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
Sanaa M. Kamal, Samer S. El Kamary, Michelle D. Shardell, Mohamed Hashem, Imad N. Ahmed, Mohamed Muhammadi, Khalifa Sayed, Ashraf Moustafa, Sarah Abdel Hakem, Amany Ibrahiem, Mohamed Moniem, Hoda Mansour, Mohamed Abdelaziz – 28 November 2007 – In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined.
Predictors of treatment in patients with chronic hepatitis C infection—Role of patient versus nonpatient factors
Fasiha Kanwal, Tuyen Hoang, Brennan M.R. Spiegel, Seth Eisen, Jason A. Dominitz, Allen Gifford, Mathew Goetz, Steven M. Asch – 28 November 2007 – Treatment with interferon and ribavirin is effective in patients with chronic infection with hepatitis C virus (HCV). Previous data indicate that treatment rates are suboptimal. We sought to identify patient and provider‐level predictors of treatment receipt in HCV by conducting a retrospective cohort study of 5701 HCV patients in a large regional Veteran's Administration (VA) healthcare network.
Reply: Geographic disparities and deceased donor liver transplantation within a single UNOS region
Marlon F. Levy – 28 November 2007
Randomized, double‐blind, placebo‐controlled trial of corticosteroids after Kasai portoenterostomy for biliary atresia
Mark Davenport, Mark D. Stringer, Sarah A. Tizzard, Patricia McClean, Giorgina Mieli‐Vergani, Nedim Hadzic – 28 November 2007 – The objective of this study was to evaluate adjuvant corticosteroids after Kasai portoenterostomy for biliary atresia. The study consisted of a prospective, 2‐center, double‐blind, randomized, placebo‐controlled trial of post–Kasai portoenterostomy corticosteroids (oral prednisolone: 2 mg/kg/day from day 7 to day 21 and 1 mg/kg/day from day 22 to day 28). The data were compared with χ2 or Mann‐Whitney tests, as appropriate.